7NW2 image
Deposition Date 2021-03-16
Release Date 2021-07-07
Last Version Date 2024-11-13
Entry Detail
PDB ID:
7NW2
Keywords:
Title:
Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-47
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.10 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:3C-like proteinase
Chain IDs:A, B
Chain Length:306
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2
Primary Citation
An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 M pro inhibitor.
Cell Chem Biol 28 1795 1806.e5 (2021)
PMID: 34174194 DOI: 10.1016/j.chembiol.2021.05.018

Abstact

Designing covalent inhibitors is increasingly important, although it remains challenging. Here, we present covalentizer, a computational pipeline for identifying irreversible inhibitors based on structures of targets with non-covalent binders. Through covalent docking of tailored focused libraries, we identify candidates that can bind covalently to a nearby cysteine while preserving the interactions of the original molecule. We found ∼11,000 cysteines proximal to a ligand across 8,386 complexes in the PDB. Of these, the protocol identified 1,553 structures with covalent predictions. In a prospective evaluation, five out of nine predicted covalent kinase inhibitors showed half-maximal inhibitory concentration (IC50) values between 155 nM and 4.5 μM. Application against an existing SARS-CoV Mpro reversible inhibitor led to an acrylamide inhibitor series with low micromolar IC50 values against SARS-CoV-2 Mpro. The docking was validated by 12 co-crystal structures. Together these examples hint at the vast number of covalent inhibitors accessible through our protocol.

Legend

Protein

Chemical

Disease

Primary Citation of related structures